ATE164522T1 - Carboxamid-modifizierte polyamin-chelatoren, radioaktive komplexe und konjugate - Google Patents

Carboxamid-modifizierte polyamin-chelatoren, radioaktive komplexe und konjugate

Info

Publication number
ATE164522T1
ATE164522T1 AT93912349T AT93912349T ATE164522T1 AT E164522 T1 ATE164522 T1 AT E164522T1 AT 93912349 T AT93912349 T AT 93912349T AT 93912349 T AT93912349 T AT 93912349T AT E164522 T1 ATE164522 T1 AT E164522T1
Authority
AT
Austria
Prior art keywords
carboxamide
conjugates
chelators
modified polyamine
complexes
Prior art date
Application number
AT93912349T
Other languages
English (en)
Inventor
William J Kruper Jr
William A Fordyce
A Dean Sherry
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Application granted granted Critical
Publication of ATE164522T1 publication Critical patent/ATE164522T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Paper (AREA)
  • Medicinal Preparation (AREA)
AT93912349T 1992-04-24 1993-04-23 Carboxamid-modifizierte polyamin-chelatoren, radioaktive komplexe und konjugate ATE164522T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/874,244 US5310535A (en) 1992-04-24 1992-04-24 Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies

Publications (1)

Publication Number Publication Date
ATE164522T1 true ATE164522T1 (de) 1998-04-15

Family

ID=25363311

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93912349T ATE164522T1 (de) 1992-04-24 1993-04-23 Carboxamid-modifizierte polyamin-chelatoren, radioaktive komplexe und konjugate

Country Status (18)

Country Link
US (2) US5310535A (de)
EP (1) EP0637253B1 (de)
JP (1) JP3850870B2 (de)
KR (1) KR100245941B1 (de)
AT (1) ATE164522T1 (de)
AU (1) AU674853B2 (de)
CA (1) CA2134092C (de)
DE (1) DE69317771T2 (de)
DK (1) DK0637253T3 (de)
ES (1) ES2114051T3 (de)
FI (1) FI944973A (de)
GR (1) GR3026533T3 (de)
HK (1) HK1006632A1 (de)
HU (1) HU222761B1 (de)
NO (1) NO304552B1 (de)
NZ (1) NZ252867A (de)
SG (1) SG49756A1 (de)
WO (1) WO1993021963A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US6099856A (en) 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5811127A (en) 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US6610329B2 (en) * 1993-04-22 2003-08-26 Emisphere Technologies Inc. Compositions for the delivery of antigens
DE69434418T2 (de) 1993-04-22 2005-12-22 Emisphere Technologies, Inc. Orale Dareichungsform
US5965121A (en) 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
GB2320248B (en) 1995-09-11 1999-04-14 Emisphere Tech Inc Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones
EP1018877A4 (de) * 1995-10-17 2000-08-09 Dovetail Technologies Inc Zell-, knochenmark- und immunistimulanzen mit niedrigerm molekulargewicht
IL126318A (en) * 1996-03-29 2004-09-27 Emisphere Tech Inc Compounds and compositions for delivering active agents and some novel carrier compounds
CA2258264A1 (en) 1996-06-14 1997-12-18 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5990166A (en) 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6358504B1 (en) * 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5939381A (en) 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5876710A (en) 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5804688A (en) 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5863944A (en) 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
EP1149066B1 (de) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Verfahren zur herstellung alkylierter salicylamide
FR2802928B1 (fr) * 1999-12-22 2003-01-31 Air Liquide Polyazacycloalcanes eventuellement greffes sur une matrice solide, complexes organometalliques les incorporant comme ligands. utilisation desdits composes a l'extraction de metaux lourds
US6565828B2 (en) 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
US6517814B2 (en) 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
HUP0400027A3 (en) 2001-02-23 2006-01-30 Bristol Myers Squibb Pharma Co Labeled macrophage scavenger receptor antagonosts for imaging atherosclerosis and vulnerable plaque
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
US7259249B2 (en) 2003-12-01 2007-08-21 Immunomedics, Inc. Method for preparing conjugates of proteins and chelating agents
EP1768558A4 (de) 2004-06-09 2009-11-25 Kereos Inc Lipophile derivate von chelat-monoamiden
US8193347B2 (en) * 2006-03-14 2012-06-05 Mallinckrodt Llc Metal complexes of tetraazamacrocycle derivatives
WO2010000714A2 (en) * 2008-07-04 2010-01-07 Oslo Universitetssykehus Hf Radioimmunoconjugate kit
US10729669B2 (en) 2015-07-28 2020-08-04 University Of Iowa Research Foundation Compositions and methods for treating cancer
WO2017223565A1 (en) 2016-06-24 2017-12-28 University Of Iowa Research Foundation Compositions and methods of treating melanoma
AU2019287595B2 (en) * 2018-04-27 2024-10-31 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US5316757A (en) * 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
US5250285A (en) * 1985-05-08 1993-10-05 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
IT1224416B (it) * 1987-12-24 1990-10-04 Bracco Ind Chimica Spa Chelanti macrociclici e loro chelati
US5057302A (en) * 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
US5049667A (en) * 1987-04-14 1991-09-17 Guerbet S.A. Nitrogen-containing cyclic ligands
US4994560A (en) * 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8719042D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
DK47389A (da) * 1988-02-03 1989-08-04 Hybritech Inc Farmakokinetisk modificerede hapten-derivater til radiomaerkning af antistoffer eller til anvendelse som radioterapeutiske midler
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
WO1989012631A1 (en) * 1988-06-24 1989-12-28 The Dow Chemical Company Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
BR8907282A (pt) * 1988-12-23 1991-03-12 Dow Chemical Co Processo para preparar complexos de metal funcionalizados com isotiocianato
GB8903023D0 (en) * 1989-02-10 1989-03-30 Parker David Chemical compounds
EP0382583B1 (de) * 1989-02-10 1996-01-17 Celltech Therapeutics Limited Aza-Macrozyklen und Verfahren zu deren Herstellung
TW213864B (de) * 1991-08-01 1993-10-01 Squibb & Sons Inc

Also Published As

Publication number Publication date
KR100245941B1 (ko) 2000-04-01
DE69317771D1 (de) 1998-05-07
WO1993021963A2 (en) 1993-11-11
DK0637253T3 (da) 1999-02-01
EP0637253A1 (de) 1995-02-08
NO304552B1 (no) 1999-01-11
FI944973A0 (fi) 1994-10-21
CA2134092A1 (en) 1993-11-11
NO944019L (no) 1994-12-12
US5310535A (en) 1994-05-10
DE69317771T2 (de) 1998-07-30
JP3850870B2 (ja) 2006-11-29
KR950701231A (ko) 1995-03-23
CA2134092C (en) 2003-07-29
EP0637253B1 (de) 1998-04-01
NO944019D0 (no) 1994-10-21
WO1993021963A3 (en) 1993-12-09
ES2114051T3 (es) 1998-05-16
AU674853B2 (en) 1997-01-16
HUT70429A (en) 1995-10-30
HK1006632A1 (en) 1999-03-05
HU222761B1 (hu) 2003-10-28
US5739323A (en) 1998-04-14
JPH07506365A (ja) 1995-07-13
SG49756A1 (en) 1998-06-15
FI944973A (fi) 1994-12-02
AU4292693A (en) 1993-11-29
GR3026533T3 (en) 1998-07-31
NZ252867A (en) 1997-03-24

Similar Documents

Publication Publication Date Title
ATE164522T1 (de) Carboxamid-modifizierte polyamin-chelatoren, radioaktive komplexe und konjugate
BR8907507A (pt) Quelante bifuncional macrociclico,seus complexos e seus conjugados com anticorpos
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
NO166267C (no) Konjugat av et maalsoekende biologisk aktivt molekyl og en forbindelse inneholdende spormerkende metall, samt diagnostisk preparat inneholdende konjugatet.
CA2001765A1 (en) Chelants possessing ortho ligating functionality and complexes thereof
FR2659478B1 (fr) Composition magnetique et ses applications.
DE69008650D1 (de) Ablenkjoch mit magnetischem Korrekturfeld und integrierter magnetischer Abschirmung.
ATE136469T1 (de) Neue verwendung eines monoklonalen antikörpers

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee